Trinomab Ranks #9 in the"2025 Top 100 Innovative Pharmaceuticals & Biologics List"
At the 9th Future Healthcare 100 Awards Ceremony held at the Suzhou International Expo Center in May 9-10, 2025, Zhuhai Trinomab BioPharmaceutical Co., Ltd. (hereinafter “Trinomab”) was honored with ranking #9 in the “2025 Future Healthcare 100 – Top 100 Innovative Pharmaceuticals & Biologics List”. This marks Trinomab’s third consecutive year in the prestigious Top 100 list, underscoring its relentless innovation and clinical impact in drug development, pipeline strategy, and therapeutic value delivery.
(Image source: Live broadcast of the awards ceremony)
(Image source: Arterial Network’s official award poster)
The four-month selection process including application submission, expert peer review and public announcement identifies the most innovative and high-potential enterprises among the candidates in the healthcare industry. Trinomab’s repeated inclusion reflects strong recognition of its scientific advancements and confidence by the peers in its future growth.
Innovative Strength: Five Novelty Models Set Industry Benchmark
The 9th Future Healthcare 100 Forum, themed “At the Tipping Point: Exploring Infinite Possibilities in New Technologies, Models, Practices, and Ecosystems,” spotlighted transformative innovations in healthcare. Since its founding in 2015, Trinomab has focused on its mission of “Creating Clinical Value” by utilizing its proprietary HitmAb? Platform—a “golden key” for development its differential pipeline of innovative human monoclonal antibody prophylaxis and therapeutics.
Leveraging this platform, Trinomab pioneered Five Novelty Models (new technologies, new targets, new mechanisms, new breakthroughs, and originative innovation) to advance novel therapeutics. A prime example is Sintetol (generic name: Siltartoxatug Injection), the global first recombinant anti-tetanus toxin mAb for prevention of tetanus, which exemplifies these models：
· New Technology: Sintetol employs Trinomab’s fourth-generation antibody technology, ensuring superior safety, efficacy and accessibility.
· New Target: Cryo-EM structural analysis revealed Sintetol binds to the AB fragment of tetanus toxin, a novel target compared to the conventional C fragment.
· New Mechanism: Sintetol blocks toxin transport and inhibits toxic enzyme activity, offering rapid passive immunity.
· New Breakthrough: Sintetol is the first Chinese biologic to receive dual Breakthrough Therapy Designation (China NMPA) and Fast Track Designation (U.S. FDA).
· Originative Innovation: As a first-in-class drug globally, Sintetol addresses unmet needs in tetanus prophylaxis.
Innovative Breakthrough: A Hardcore Solution Breaking Free from Blood Dependence
Developed under the "Five New Models," “the next-generation "tetanus shot," Sintetol obtained marketing approval granted by China NMPA on February 11, 2025. It provides rapid emergency protection through intramuscular injection with advantage of no need for skin testing and post injection observation (for outpatients), no need for dose adjustment based on body weight or wound size and longer protective antibody level compared to the traditional HTIG.
For tetanus, a potentially fatal disease, it remains a public health challenge urgently needing solution globally, especially in regions with scarce medical resources. Traditional passive immunization agents have many limitations, while Sintetol leverages its outstanding advantages in safety, efficacy, controllability, and accessibility. In March 2025, the first dose of Sintetol was administered at the Zhuhai People’s Hospital, inaugurating a new chapter in clinical application, providing a more efficient solution for tetanus prevention and treatment, and marking a key step for Trinomab on the commercialization path of innovative drugs.
In addition to Sintetol, Trinomab has 2 products in phase I study including anti-NGF antibody for pain control and anti-VZV antibody for prevention of severe VZV infection, and one in phase III study. Noticeablely, retavibart, an anti-RSV antibi prophylaxis for prevention of severe RSV infection developed by Trinomab, has achieved all primary and secondary efficacy end points in Phase III trial and now is approaching to the end of phase III trial. There are also a number of products in the various stages of early development with promising and stead progress. Trinomab is also actively engaging in global cooperation, integrating superior resources to accelerate achievement transformation and enhance competitiveness and influence.
Future Outlook: Advancing from "Fast-Follow" to "First-in-Class"
Amid the global innovation wave, China’s medical and healthcare industry is transitioning from market sales-driven to R&D innovation-driven, where even minor innovations can become key forces pushing the industry to new heights. Looking ahead, Trinomab will continue to deepen its focus on innovative drug R&D, uphold the vision of "Regardless of Poverty or Wealth, Sickness or Health, We and Our Products Will Eventually Reach," and leap from "Fast-Follow" to "A First-in-Class" through the dual drive of "clinical needs + innovative technologies," delivering a breakthrough answer of "Made in China" to the world.
(Sintetol Trademark Registration Number: 74174546)
